18 . 06 .2025
Press release
ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years
17 . 06 .2025
Press release
Galderma establishes new U.S. headquarters in Miami and strengthens regional leadership
06 . 06 .2025
News story
Revolutionizing Atopic Dermatitis 2025 Conference: Galderma’s Scientific Presentations
06 . 06 .2025
Press release
RAD 2025: Long-term data on Nemluvio® (nemolizumab) demonstrate its favorable safety profile and sustained and increased improvements in itch and skin lesions in patients with atopic dermatitis up to two years
05 . 06 .2025
News story
International Congress of Dermatology 2025: Galderma’s Scientific Presentations
28 . 05 .2025
Press release
Galderma buys back shares worth CHF 233 million in the context of accelerated bookbuild offering
27 . 05 .2025
Press release
Galderma intends to buy back approximately 2.4 million shares in the context of the accelerated bookbuild offering by EQT, ADIA and Auba
24 . 04 .2025
Press release
Galderma delivers record first quarter net sales of 1.129 billion USD, including strong performance from two launches with blockbuster potential, and confirms full-year guidance
23 . 04 .2025
Press release
Galderma shareholders approve all Annual General Meeting proposals